Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy

Programmed death-ligand 1 (PD-L1) expression in tumor tissue is under investigation as a candidate biomarker in immuno-oncology dug development. The soluble form of PD-L1 (sPDL1) is suggested to have immunosuppressive activity. In this study, we measured the serum level of sPDL1 and evaluated its pr...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget Vol. 7; no. 47; pp. 76604 - 76612
Main Authors: Ha, Hyerim, Nam, Ah-Rong, Bang, Ju-Hee, Park, Ji-Eun, Kim, Tae-Yong, Lee, Kyung-Hun, Han, Sae-Won, Im, Seock-Ah, Kim, Tae-You, Bang, Yung-Jue, Oh, Do-Youn
Format: Journal Article
Language:English
Published: United States 22.11.2016
Subjects:
Adult
Aged
B7-H1 Antigen - blood
Bile Duct Neoplasms - blood
Bile Duct Neoplasms - diagnosis
Bile Duct Neoplasms - drug therapy
Bile Duct Neoplasms - mortality
Biomarkers
Chemotherapy, Adjuvant
Female
Humans
Leukocyte Count
Lymphocytes
Male
Middle Aged
Neoplasm Staging
Neutrophils
Palliative Care
Prognosis
Treatment Outcome
biliary tract cancer
PDL1
biomarker
soluble PDL1
immunotherapy
ISSN:1949-2553
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Programmed death-ligand 1 (PD-L1) expression in tumor tissue is under investigation as a candidate biomarker in immuno-oncology dug development. The soluble form of PD-L1 (sPDL1) is suggested to have immunosuppressive activity. In this study, we measured the serum level of sPDL1 and evaluated its prognostic implication in biliary tract cancer (BTC). Blood was collected from 158 advanced BTC patients (68 intrahepatic cholangiocarcinoma, 56 gallbladder cancer, 22 extrahepatic cholangiocarcinoma and 12 ampulla of vater cancer) before initiation of palliative chemotherapy. Serum sPDL1 was measured using an enzyme-linked immunosorbent assay. Clinical data included neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII, neutrophil × platelet/lymphocyte). The patients were assigned to two cohorts (training and validation cohort) using a simple random sampling method to validate the cut-off value of each marker. Validation was performed using a twofold cross-validation method. Overall survival (OS) of all patients was 9.07 months (95% CI: 8.20-11.33). Median sPDL1 was 1.20 ng/mL (range 0.03-7.28, mean 1.50, SD 1.22). Median NLR, PLR and SII were 2.60, 142.85 and 584.93, respectively. Patients with high sPDL1 (≥0.94 ng/mL) showed worse OS than patients with low sPDL1 (7.93 vs. 14.10 months, HR 1.891 (1.35-2.65), p<0.001). In multivariate analysis, high sPDL1 and NLR were independent poor prognostic factors. In conclusion, serum sPDL1 can be measured and has significant role on the prognosis of advanced BTC patients treated with palliative chemotherapy.
AbstractList Programmed death-ligand 1 (PD-L1) expression in tumor tissue is under investigation as a candidate biomarker in immuno-oncology dug development. The soluble form of PD-L1 (sPDL1) is suggested to have immunosuppressive activity. In this study, we measured the serum level of sPDL1 and evaluated its prognostic implication in biliary tract cancer (BTC). Blood was collected from 158 advanced BTC patients (68 intrahepatic cholangiocarcinoma, 56 gallbladder cancer, 22 extrahepatic cholangiocarcinoma and 12 ampulla of vater cancer) before initiation of palliative chemotherapy. Serum sPDL1 was measured using an enzyme-linked immunosorbent assay. Clinical data included neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and systemic immune-inflammation index (SII, neutrophil × platelet/lymphocyte). The patients were assigned to two cohorts (training and validation cohort) using a simple random sampling method to validate the cut-off value of each marker. Validation was performed using a twofold cross-validation method. Overall survival (OS) of all patients was 9.07 months (95% CI: 8.20-11.33). Median sPDL1 was 1.20 ng/mL (range 0.03-7.28, mean 1.50, SD 1.22). Median NLR, PLR and SII were 2.60, 142.85 and 584.93, respectively. Patients with high sPDL1 (≥0.94 ng/mL) showed worse OS than patients with low sPDL1 (7.93 vs. 14.10 months, HR 1.891 (1.35-2.65), p<0.001). In multivariate analysis, high sPDL1 and NLR were independent poor prognostic factors. In conclusion, serum sPDL1 can be measured and has significant role on the prognosis of advanced BTC patients treated with palliative chemotherapy.
Author Bang, Ju-Hee
Lee, Kyung-Hun
Han, Sae-Won
Oh, Do-Youn
Park, Ji-Eun
Ha, Hyerim
Nam, Ah-Rong
Kim, Tae-You
Kim, Tae-Yong
Im, Seock-Ah
Bang, Yung-Jue
Author_xml – sequence: 1
  givenname: Hyerim
  surname: Ha
  fullname: Ha, Hyerim
  organization: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
– sequence: 2
  givenname: Ah-Rong
  surname: Nam
  fullname: Nam, Ah-Rong
  organization: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– sequence: 3
  givenname: Ju-Hee
  surname: Bang
  fullname: Bang, Ju-Hee
  organization: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– sequence: 4
  givenname: Ji-Eun
  surname: Park
  fullname: Park, Ji-Eun
  organization: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Tae-Yong
  surname: Kim
  fullname: Kim, Tae-Yong
  organization: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
– sequence: 6
  givenname: Kyung-Hun
  surname: Lee
  fullname: Lee, Kyung-Hun
  organization: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– sequence: 7
  givenname: Sae-Won
  surname: Han
  fullname: Han, Sae-Won
  organization: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– sequence: 8
  givenname: Seock-Ah
  surname: Im
  fullname: Im, Seock-Ah
  organization: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– sequence: 9
  givenname: Tae-You
  surname: Kim
  fullname: Kim, Tae-You
  organization: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– sequence: 10
  givenname: Yung-Jue
  surname: Bang
  fullname: Bang, Yung-Jue
  organization: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– sequence: 11
  givenname: Do-Youn
  surname: Oh
  fullname: Oh, Do-Youn
  organization: Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27780932$$D View this record in MEDLINE/PubMed
BookMark eNo1kMFO3DAQhq2KqlDKA_RS-bgcArGdOM4R0dJWWgFq4bwaO7MbI8cOtrPVPldfEKPSuYzm1zf_aP6P5MgHj4R8ZvUFU1Lwy-BNyBB3mC8YV6x-R05Y3_QVb1txTM5SeqpLtU2neP-BHPOuU3Uv-An5-zu4RTukcwy7CNOEAx0Q8lg5uwM_UEZX6f7rmp3T18njkmOYR-uqHCp3mOYxmENGGiHbQFe361_nxQoHa3KiaYl7uwdHracw7MGb4q6tsxAPNEcwmZpXMdK5rKMvKzmW44X6Y_NYVFfYbPdIzYhTyCNGmA-fyPstuIRnb_2UPN58e7j-Ua3vvv-8vlpXRvR9roxREkXT1lo3Wy0RNcNuCz1g07K6M6aX2DWDRiFB1JJJKYaWK4XQcWg18FOy-udbsnleMOXNZJNB58BjWNKGKdFK1XFZF_TLG7roEuFmjnYqT27-B81fADdzhuk
CitedBy_id crossref_primary_10_1002_jcp_27373
crossref_primary_10_3389_fonc_2024_1494051
crossref_primary_10_3390_cancers13123034
crossref_primary_10_1002_cam4_2789
crossref_primary_10_1007_s00268_021_06346_3
crossref_primary_10_3390_cells12060846
crossref_primary_10_1186_s12885_020_6612_2
crossref_primary_10_1016_j_phrs_2021_105741
crossref_primary_10_1007_s00384_019_03356_5
crossref_primary_10_1097_TA_0000000000001921
crossref_primary_10_1007_s00262_021_03103_2
crossref_primary_10_3390_cancers13225671
crossref_primary_10_3389_fimmu_2020_587460
crossref_primary_10_3390_jcm9082536
crossref_primary_10_1111_liv_14636
crossref_primary_10_3389_fimmu_2023_1119168
crossref_primary_10_3390_ijerph17051742
crossref_primary_10_1007_s00277_023_05325_z
crossref_primary_10_1186_s12957_022_02783_z
crossref_primary_10_1016_j_biopha_2024_116659
crossref_primary_10_3390_cancers12020473
crossref_primary_10_3389_fonc_2020_626932
crossref_primary_10_3389_fimmu_2023_1133883
crossref_primary_10_1038_s41598_019_47330_1
crossref_primary_10_1080_2162402X_2020_1832348
crossref_primary_10_1080_17474124_2021_1912591
crossref_primary_10_1097_MD_0000000000005895
crossref_primary_10_3390_cancers12020361
crossref_primary_10_1007_s00262_023_03513_4
crossref_primary_10_1007_s10637_017_0548_7
crossref_primary_10_1038_s41577_019_0264_y
crossref_primary_10_1177_10732748221076805
crossref_primary_10_1111_liv_14098
crossref_primary_10_3389_fonc_2019_00897
crossref_primary_10_3389_fonc_2021_774131
crossref_primary_10_1007_s00262_019_02387_9
crossref_primary_10_1245_s10434_018_07112_x
crossref_primary_10_1136_bmjopen_2021_050112
crossref_primary_10_3390_jcm11164815
crossref_primary_10_1038_s41598_022_16727_w
crossref_primary_10_1038_s41598_023_33128_9
crossref_primary_10_1186_s12931_018_0885_x
crossref_primary_10_1038_s41392_020_00324_2
crossref_primary_10_3389_fonc_2023_1170220
crossref_primary_10_1093_annonc_mdz196
crossref_primary_10_2147_OTT_S269671
crossref_primary_10_1007_s12029_021_00596_z
crossref_primary_10_3389_fimmu_2021_651634
crossref_primary_10_1111_sji_12596
crossref_primary_10_1016_j_cca_2018_04_023
crossref_primary_10_1080_1354750X_2023_2198168
crossref_primary_10_3390_genes8020076
crossref_primary_10_1016_j_cca_2017_09_006
crossref_primary_10_3390_cancers14020438
crossref_primary_10_3390_cancers17030555
crossref_primary_10_1002_cam4_2373
crossref_primary_10_2147_CMAR_S312690
crossref_primary_10_1007_s11864_017_0486_9
crossref_primary_10_1002_ams2_363
crossref_primary_10_1111_his_13254
crossref_primary_10_1002_ijc_33751
crossref_primary_10_1016_j_intimp_2022_109526
crossref_primary_10_1007_s00261_021_02975_3
crossref_primary_10_1097_MD_0000000000017231
crossref_primary_10_3390_microorganisms9030603
crossref_primary_10_1080_01635581_2022_2121845
crossref_primary_10_1097_MD_0000000000009617
crossref_primary_10_1097_MEG_0000000000001021
crossref_primary_10_3390_cancers15041062
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.18632/oncotarget.12810
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
EISSN 1949-2553
EndPage 76612
ExternalDocumentID 27780932
Genre Journal Article
GroupedDBID ---
53G
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CGR
CUY
CVF
DIK
ECM
EIF
FRJ
GX1
HYE
KQ8
M48
M~E
NPM
OK1
PGMZT
RPM
7X8
ID FETCH-LOGICAL-c399t-cc86e3450bb4fb6eeb1e7fa9ae45107cc96e74dbe36a3061663d5288ea72a5ba2
IEDL.DBID 7X8
ISICitedReferencesCount 87
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000389633400021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
IngestDate Sun Nov 09 09:27:24 EST 2025
Thu Jan 02 23:12:09 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 47
Keywords biliary tract cancer
PDL1
biomarker
soluble PDL1
immunotherapy
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c399t-cc86e3450bb4fb6eeb1e7fa9ae45107cc96e74dbe36a3061663d5288ea72a5ba2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=12810&path%5B%5D=40586
PMID 27780932
PQID 1835687260
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_1835687260
pubmed_primary_27780932
PublicationCentury 2000
PublicationDate 2016-11-22
PublicationDateYYYYMMDD 2016-11-22
PublicationDate_xml – month: 11
  year: 2016
  text: 2016-11-22
  day: 22
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Oncotarget
PublicationTitleAlternate Oncotarget
PublicationYear 2016
References 25641673 - Pancreatology. 2015 Mar-Apr;15(2):145-50
20551066 - Cancer Res. 2010 Jul 1;70(13):5326-36
18500231 - Nat Rev Immunol. 2008 Jun;8(6):467-77
12091876 - Nat Med. 2002 Aug;8(8):793-800
25669979 - Oncotarget. 2015 Mar 10;6(7):5449-64
21185705 - Curr Opin Immunol. 2011 Apr;23(2):286-92
24089443 - Clin Cancer Res. 2013 Oct 1;19(19):5300-9
19188168 - Clin Cancer Res. 2009 Feb 1;15(3):971-9
20143437 - Cancer. 2010 Apr 1;116(7):1757-66
26515600 - Oncotarget. 2015 Dec 1;6(38):41228-36
21376230 - Cell. 2011 Mar 4;144(5):646-74
24714771 - Clin Cancer Res. 2014 Oct 1;20(19):5064-74
25891174 - N Engl J Med. 2015 May 21;372(21):2018-28
26258846 - Nat Genet. 2015 Sep;47(9):1003-10
25605845 - J Clin Oncol. 2015 Jun 10;33(17 ):1974-82
22146893 - Cancer Immunol Immunother. 2012 Jul;61(7):1019-31
25271081 - Clin Cancer Res. 2014 Dec 1;20(23):6212-22
24416729 - Cancer Immunol Res. 2013 Jul;1(1):54-63
8671665 - Int Immunol. 1996 May;8(5):765-72
24630393 - Eur J Cancer. 2014 Jun;50(9):1581-9
10436847 - Ann Oncol. 1999;10 Suppl 4:308-11
22454286 - Cancer Res. 2012 May 15;72(10):2683-91
19436294 - Br J Cancer. 2009 Jun 2;100(11):1765-70
21355078 - Clin Cancer Res. 2011 Apr 1;17(7):1915-23
25825511 - J Natl Cancer Inst. 2015 Mar 30;107(6):djv048
19085911 - Hepatology. 2009 Jan;49(1):116-23
18049334 - J Immunother. 2007 Nov-Dec;30(8):825-30
25891173 - N Engl J Med. 2015 Jun 25;372(26):2521-32
21221967 - Cancer Immunol Immunother. 2011 Mar;60(3):433-42
8910964 - Stat Med. 1996 Oct 30;15(20):2203-13
22777737 - Eur J Immunol. 2012 Oct;42(10):2584-96
22677156 - Lancet Oncol. 2012 Jul;13(7):688-95
24732592 - Leukemia. 2014 Dec;28(12):2367-75
References_xml – reference: 20143437 - Cancer. 2010 Apr 1;116(7):1757-66
– reference: 10436847 - Ann Oncol. 1999;10 Suppl 4:308-11
– reference: 25669979 - Oncotarget. 2015 Mar 10;6(7):5449-64
– reference: 21221967 - Cancer Immunol Immunother. 2011 Mar;60(3):433-42
– reference: 19085911 - Hepatology. 2009 Jan;49(1):116-23
– reference: 24089443 - Clin Cancer Res. 2013 Oct 1;19(19):5300-9
– reference: 24714771 - Clin Cancer Res. 2014 Oct 1;20(19):5064-74
– reference: 24732592 - Leukemia. 2014 Dec;28(12):2367-75
– reference: 21185705 - Curr Opin Immunol. 2011 Apr;23(2):286-92
– reference: 22146893 - Cancer Immunol Immunother. 2012 Jul;61(7):1019-31
– reference: 19188168 - Clin Cancer Res. 2009 Feb 1;15(3):971-9
– reference: 22777737 - Eur J Immunol. 2012 Oct;42(10):2584-96
– reference: 22677156 - Lancet Oncol. 2012 Jul;13(7):688-95
– reference: 21376230 - Cell. 2011 Mar 4;144(5):646-74
– reference: 26515600 - Oncotarget. 2015 Dec 1;6(38):41228-36
– reference: 25891174 - N Engl J Med. 2015 May 21;372(21):2018-28
– reference: 18049334 - J Immunother. 2007 Nov-Dec;30(8):825-30
– reference: 24416729 - Cancer Immunol Res. 2013 Jul;1(1):54-63
– reference: 21355078 - Clin Cancer Res. 2011 Apr 1;17(7):1915-23
– reference: 26258846 - Nat Genet. 2015 Sep;47(9):1003-10
– reference: 18500231 - Nat Rev Immunol. 2008 Jun;8(6):467-77
– reference: 25271081 - Clin Cancer Res. 2014 Dec 1;20(23):6212-22
– reference: 25605845 - J Clin Oncol. 2015 Jun 10;33(17 ):1974-82
– reference: 8671665 - Int Immunol. 1996 May;8(5):765-72
– reference: 22454286 - Cancer Res. 2012 May 15;72(10):2683-91
– reference: 25641673 - Pancreatology. 2015 Mar-Apr;15(2):145-50
– reference: 19436294 - Br J Cancer. 2009 Jun 2;100(11):1765-70
– reference: 25891173 - N Engl J Med. 2015 Jun 25;372(26):2521-32
– reference: 20551066 - Cancer Res. 2010 Jul 1;70(13):5326-36
– reference: 24630393 - Eur J Cancer. 2014 Jun;50(9):1581-9
– reference: 25825511 - J Natl Cancer Inst. 2015 Mar 30;107(6):djv048
– reference: 12091876 - Nat Med. 2002 Aug;8(8):793-800
– reference: 8910964 - Stat Med. 1996 Oct 30;15(20):2203-13
SSID ssj0000547829
Score 2.4546015
Snippet Programmed death-ligand 1 (PD-L1) expression in tumor tissue is under investigation as a candidate biomarker in immuno-oncology dug development. The soluble...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 76604
SubjectTerms Adult
Aged
B7-H1 Antigen - blood
Bile Duct Neoplasms - blood
Bile Duct Neoplasms - diagnosis
Bile Duct Neoplasms - drug therapy
Bile Duct Neoplasms - mortality
Biomarkers
Chemotherapy, Adjuvant
Female
Humans
Leukocyte Count
Lymphocytes
Male
Middle Aged
Neoplasm Staging
Neutrophils
Palliative Care
Prognosis
Treatment Outcome
Title Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
URI https://www.ncbi.nlm.nih.gov/pubmed/27780932
https://www.proquest.com/docview/1835687260
Volume 7
WOSCitedRecordID wos000389633400021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na9swFBddu0Mv28q-snXlDXZID1ptWbaUUylbSw9ZCKWD3IIkS20gtbPYKeTv6j_Y9xxlPQ0Kuxhb-Ave008_vU_Gvmmba6N8wq30GZciWK7zMuUBhY3rv6KejF2zCTUa6clkMI4GtyaGVW4xsQPqsnZkIz9B1csLrZB-ny7-cOoaRd7V2ELjBdvLkMpQSJea6L82loSKVYlBdGbqIhMnNZU86GKsv5MPKfk3sewWmIvX__trb9irSC3hbKMLB2zHV2_ZA9m97NxDDMTCD0NJtI_PZzemKiGFfjP-OUyPga4qv2qX9eJ2NudtzedrlHXt1q2HTlGgPxpeHeOryLvTNtCsEGhQVWFWwTaYACja1izX0FL-FTgaXEIs39pAF9iOd5H9F0fJ2EOAC6g7dzEZbP2O_b44v_5xyWOjBu6Q37TcOV34TOaJtTLYwiP-exWo7rfEKa-cGxReydL6rDC4RUmR5ZS50NobJUxujXjPdqu68h8ZOETgYArcl5ZBZjYbSGtMLg2ehDQNvse-bmUwxYlA3g1T-XrVTJ-k0GMfNoKcLjYVO6ZCKZ0gU_30jKc_s30kRQXlGwpxyPYCwoD_wl66-3bWLI86DcPjaPzrEdPM4mU
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Soluble+programmed+death-ligand+1+%28sPDL1%29+and+neutrophil-to-lymphocyte+ratio+%28NLR%29+predicts+survival+in+advanced+biliary+tract+cancer+patients+treated+with+palliative+chemotherapy&rft.jtitle=Oncotarget&rft.au=Ha%2C+Hyerim&rft.au=Nam%2C+Ah-Rong&rft.au=Bang%2C+Ju-Hee&rft.au=Park%2C+Ji-Eun&rft.date=2016-11-22&rft.eissn=1949-2553&rft.volume=7&rft.issue=47&rft.spage=76604&rft_id=info:doi/10.18632%2Foncotarget.12810&rft_id=info%3Apmid%2F27780932&rft_id=info%3Apmid%2F27780932&rft.externalDocID=27780932